



CONTINUING MEDICAL EDUCATION

Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations^{☆,☆☆}



Guilherme Canho Bittner ^{a,b,*}, Felipe Bochnia Cerci ^{c,d,e}, Elisa Mayumi Kubo ^f, Stanislav N. Tolkachjov ^g

^a Dermatology Service, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil

^b Private Practice, Campo Grande, MS, Brazil

^c Dermatology Service, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazil

^d Private Practice, Curitiba, PR, Brazil

^e Post-graduate Program – Internal Medicine and Health Sciences, Universidade Federal do Paraná, Curitiba, Brazil

^f Private Practice, Porto União, PR, Brazil

^g Epiphany Dermatology, Dallas, TX, United States

Received 15 July 2020; accepted 5 October 2020

Available online 24 March 2021

KEYWORDS

Carcinoma, basal cell;
Diagnostic techniques, surgical;
Minor surgical procedures;
Mohs surgery;
Neoplasms

Abstract Mohs micrographic surgery is a specialized form of skin cancer surgery that has the highest cure rates for several cutaneous malignancies. Certain skin cancers can have small extensions or “roots” that may be missed if an excised tumor is serially cross-sectioned in a “bread-loaf” fashion, commonly performed on excision specimens. The method of Mohs micrographic surgery is unique in that the dermatologist (Mohs surgeon) acts as both surgeon and pathologist, from the preoperative considerations until the reconstruction. Since Dr. Mohs’s initial work in the 1930s, the practice of Mohs micrographic surgery has become increasingly widespread among the dermatologic surgery community worldwide and is considered the treatment of choice for many common and uncommon cutaneous neoplasms. Mohs micrographic surgery spares the maximal amount of normal tissue and is a safe procedure with very few complications, most of them managed by Mohs surgeons in their offices. Mohs micrographic surgery is the standard of care for high risks basal cell carcinomas and cutaneous squamous cell carcinoma and is commonly and increasingly used for melanoma and other rare tumors with superior cure rates. This review better familiarizes the dermatologists with the technique, explains the difference between Mohs micrographic surgery and wide local excision, and discusses its main indications.

© 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

[☆] How to cite this article: Bittner GC, Cerci FB, Kubo EM, Tolkachjov SN. Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations. An Bras Dermatol. 2021;96:263–77.

^{☆☆} Study conducted at the Dermatology Service, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil; Dermatology Service, Universidade Federal do Paraná, Curitiba, PR, Brazil and Epiphany Dermatology, Dallas, Tx, United States.

* Corresponding author.

E-mails: guilhermebittner@gmail.com, clinchans@outlook.com (G.C. Bittner).

<https://doi.org/10.1016/j.abd.2020.10.004>

0365-0596/© 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Mohs micrographic surgery (MMS) is a specialized form of skin cancer surgery that has the highest cure rates for several cutaneous malignancies.¹⁻⁵ The technique allows complete histopathological analysis of the peripheral and deep surgical margins and minimizes tissue removal, sparing normal tissue (Fig. 1). Certain skin cancers can have small extensions or "roots" that can be missed if an excised tumor is serially cross-sectioned in a "bread-loaf" fashion, commonly performed on excision specimens (Fig. 2).^{6,7}

Approximately 75% of all nonmelanoma skin cancer (NMSCs) are basal cell carcinoma (BCC), whereas cutaneous squamous cell carcinoma (SCC) represent approximately 20%, and the remaining are melanomas (4%) and other rare tumors.⁸ MMS is the standard of care for selected BCCs and SCCs and is commonly and increasingly used for melanomas and other tumors.⁵

MMS is unique in that the dermatologist (Mohs surgeon) acts as both surgeon and pathologist allowing precise correlation of the surgical wound with the Mohs map.⁶ Once clear margins are obtained; the Mohs surgeon may perform same-day reconstruction unless multi-specialty referrals are needed.

History

Dr. Frederic E. Tromovitch (1932-1990), started his work in what he called "chemosurgery" in the 1930s, but his findings were not published until 1941.⁹ In 1936, he started using this technique in patients deemed incurable. He would apply a 20% zinc chloride paste on the skin cancer in vivo and leave it overnight to fixate the skin. While painful for the patient, this was quite effective in preserving the microscopic anatomy of the skin.^{2,6}

In the 1960s, Dr. Theodore Mohs (1910-2002), first published an article using the fresh tissue technique on tumors located on other parts of the body (Dr. Mohs first did it in 1953 but it was not published).¹⁰ The modifications by Dr. Tromovitch of Dr. Mohs's technique enabled the procedure to be done in a single day.⁶ Mohs presented his data, a cohort of 70 basal cell carcinoma (BCCs) on the eyelid removed with the fresh-frozen technique, in 1969. The following year, Dr. Theodore Tromovitch published a series of an additional 75 cases successfully treated with the fresh-frozen technique. These findings further validated the efficacy of this method.² The fresh-frozen tissue technique quickly became the standard of care, and in 1987, the American College of Chemosurgery was renamed as the American College of Mohs Surgery and Cutaneous Oncology to reflect this practice.²




Figure 1 Mohs micrographic surgery. (A), Demarcation of the visible tumor and excision with a 1–2-mm margin. The incision is made with the scalpel angled at 45-degrees, which allows flattening the surgical margins on the same plane. (B), (1) Surgical specimen. The surgical margins that must be examined correspond to all lateral and deep external areas of the fragment. (2) The red arrows indicate the "flattening" of the margins to the same plane. (3) After the fragment is frozen in the cryostat, "horizontal" histological sections are performed allowing the analysis of 100% of the lateral and deep margins. The three dark spots correspond to the "roots" of the tumor seen on microscopic examination. (C), The remaining tumor "roots" are excised for further analysis under the microscope.




Figure 2 Wide local excision. (A), Elliptical excision with a wide surgical margin around the tumor. (B), Surgical specimen. On the upper drawing, the dotted lines indicate how the fragment is sectioned, similar to a loaf of bread ("bread loaf" analysis). These sections represent only about 1% of the surgical margins and may fail to see the tumor roots during microscopic examination. The three dots correspond to the tumor roots that "were left" in the patient, but were not seen in the microscopic examination because they were not included in the examined histological sections. (C), Correlation between material from surgical excision and detection of the tumor in longitudinal sections. The blue arrows indicate the histological sections that are seen in "bread loaf" analysis. Note the large amount of unexamined margins (bottom drawing) in this method.

Since Dr. Mohs's initial work in the 1930s, the practice of MMS has become increasingly widespread among the dermatologic surgery community worldwide and is now considered the treatment of choice for many common and uncommon cutaneous neoplasms.¹¹⁻¹⁵

MMS training

In the US and Brazil, only dermatology-trained physicians are allowed to apply for a fellowship in MMS, and a minimum of 12 months of supervised training under the program director is required. The fellow must review all pathology from the surgical cases done in the training program. Some practical components of the training program are different between the two countries, especially regarding the number of cases (much higher in the US).

The main objective of the training is to become able to evaluate the histopathology of the section, especially tumor-free margins (normal skin). Mohs surgeons must also have expertise in skin reconstruction, repairing most of the cases, to optimize functional and aesthetic outcomes.

In Brazil, the Brazilian Society of Dermatology has a certification in micrographic surgery for the dermatologic surgeons that fulfill the training program.¹⁶ Most programs are affiliated to a residency program. In the US, MMS training programs are accredited by the Accreditation Council for Graduate Medical Education (ACGME) and the American College of Mohs Surgery (ACMS). While some fellowship programs, private and academic practices, were originally accredited by the ACMS, all US-based fellowships now have to be ACGME approved, while a few international fellowships still carry an ACMS approval but not ACGME. Most of these fellowship directors were trained in the US and started fellowships in other countries. Other societies like the American Society for Dermatologic Surgery (ASDS) and the American Society for Mohs Surgery (ASMS) have dermatologic surgical programs but are not formal Mohs fellowships. The ASDS also has fellowships in cosmetic surgery that may share the same fellowship directors as the ACMS Mohs surgery programs.

In October of 2018, the American Board of Medical Specialties (ABMS) approved the American Board of Dermatology (ABD) for a new board certification in Micrographic Dermatologic Surgery (MDS).¹⁷ According to ABD, candidates for the MDS subspecialty certification must:

- 1 Possess a current, valid, full, and unrestricted license to practice medicine or osteopathy in at least one state or province within the United States or Canada;
- 2 Hold primary certification in general dermatology from ABD;
- 3 Be up to date in Maintenance of Certification (MOC) if certification by ABD is time-limited;
- 4 Demonstrate experience in the subspecialty by successfully completing the ACGME-accredited Micrographic Surgery and Dermatologic Oncology (MSDO) fellowship OR during an initial 5-year practice pathway eligibility period only, attesting to practicing micrographic surgery; and
- 5 Pass the MDS certification examination.¹⁷

While it is not fully known if the ACMS will accept those who have passed the MDS examination and met the aforementioned requirements or if other societies will continue to keep a separate certification and meetings, after the 5-year period, all candidates to become Mohs surgeons must train in an ACGME-accredited Mohs surgery fellowship and meet the MDS requirements. In addition, private-practice fellowships will likely be decreasing in numbers and limited in the upcoming years, as a sponsoring institution with a dermatology residency is now required for a fellowship program.

Preoperative considerations

Prophylactic antibiotics

Most patients do not require prophylactic antibiotics. However, in some cases it is indicated for one of the following reasons: reduce the likelihood of surgical site infection, risk of endocarditis, and risk of prosthetic infection. To reduce surgical site infection, the main indications consist of surgeries on the lower extremities (mainly legs) and groins, wedge excision of ear or lip, flaps on the nose, and grafts.¹⁸

Antibiotic choices include oral cephalexin 2 g or, for penicillin-allergic patients, clindamycin 600 mg. If the preoperative antibiotic dose was missed inadvertently, the medication may be given up to 2 -hs after the procedure.¹⁸ In addition, there are publications showing success with clindamycin mixed with lidocaine for additional intra-incisional local antibiotic coverage.¹⁹⁻²¹

Anticoagulants

Prior to cutaneous surgery, a discussion of whether to continue anticoagulation medications is necessary. It is important to weigh the risks and benefits of stopping medications vs continuing.²² In general, if the patient has a history of thrombotic events (secondary prevention), medications should be continued. If they are used for primary prevention and the risk of bleeding may significantly impair the surgical outcome, discussion with the primary care provider whether to stop or not is an option. Otherwise, the recommendation is to continue.²³

In 2011, a study demonstrated that clopidogrel was 28 times more likely than no anticoagulation and 6 times more likely than aspirin to result in severe complications after MMS (including bleeding, hematoma, and infection). However, complications were not life-threatening.²⁴ In another study with 2,790 patients, 68 underwent surgery while taking warfarin (2.4%). Intraoperative bleeding was easily controlled, and postoperative bleeding was not recorded in any of the patients.²⁵ Dabigatran and Rivaroxaban did not demonstrate severe hemorrhagic bleeding.^{23,26}

It is also important to note that serious adverse vascular events have been reported after discontinuation of anticoagulants. In some cases, these thrombotic events have resulted in serious impairment or death.²⁷ Based on the literature, medically necessary anticoagulant and antiplatelet medication should be continued during MMS. In general, bleeding complications are uncommon and easy to manage. Special attention must be paid to achieving intraopera-

tive hemostasis. The use of pressure bandages should be considered in patients taking anticoagulants, in particular, clopidogrel and warfarin.²²

Pacemakers and implantable cardiac defibrillators

The use of electrocautery to achieve hemostasis is of particular concern in patients with a pacemaker, Implantable Cardioverter Defibrillator (ICD), or other implantable medical devices.² A retrospective chart review of patients with pacemakers (n=173) or ICDs (n=13) submitted to MMS or WLE had no documented complications from electrocautery.²⁸

An *in vitro* study concluded that hyfrecators are safe to use in patients with defibrillators. The authors investigated safety margins and reported that for pacemakers, atrial inhibition was observed at 3 cm on maximum hyfrecator settings and 1 cm at normal use settings.²⁹ A recent *in vivo* retrospective study did not report adverse perioperative effects in patients with implantable cardiac devices.³⁰

The lack of complications associated with pacemakers and ICDs during electrocautery is reassuring. The authors support published recommendations about techniques and precautions to optimize safety during electrocautery in patients with cardiac devices. The care of patients with ICDs, in particular, requires special consideration.²⁸ The discussion with the assistant cardiologist is important since some cardiac devices can be temporarily turned off with a magnet.³¹ Another possibility in some cases is the use of disposable electrocautery.

Classical surgical technique

The first stage of MMS is marking the clinically evident tumor margins to be excised (usually from 1 to 2 mm). This may be done with the help of surgical magnifying glasses or a dermatoscope. After the marking, the area is cleansed with antiseptic and local anesthesia is done, typically with buffered lidocaine with epinephrine. Then, the clinically evident tumor is removed (debulking) with either a blade (sharp debulking) or a curette, being careful not to erase surgical markings. Next, first stage margins are removed with the blade oriented at a 45-degree angle to the skin.⁵ Beveling of the scalpel blade allows for proper alignment of the peripheral edges of the tissue specimen during the preparation of the histopathological specimen. During first stage excision, markings are done at the 12, 3, and 6 o'clock positions for further orientation allowing location of residual tumor (in case the residual tumor is detected during microscopic examination).

Once the specimen is entirely removed, hemostasis is obtained. Some surgeons inject an additional long lasting anesthetic (bupivacaine 0.5%) to prevent local pain while the patient awaits the laboratory processing of the specimen and the reading of the histologic slides.³² While tissue is processed (20-min to 1-h), the patient awaits, with a bandage on the wound, in a waiting room or in the surgical room.

The first step of tissue processing is to flatten the surgical specimen, ensuring that the beveled peripheral margins are on the same plane as the deep margin. Tissue may be addi-

tionally flattened with relaxing incisions. Next, markings are inked with different colors (chromacoding). For correlation with the surgical defect, a two-dimensional map of the lesion and corresponding area is drawn using the same colors to identify each marking. Another option is to create a digital Mohs map by photographing the wound area and coloring the markings on the tablet/computer.^{33,34} The choice of mapping is influenced by surgeon preference or training and added to the clinic protocol. The specimen is then frozen surrounded by a specific gel called Optimum Cutting Temperature (OCT) and fixed to a chuck. Finally, the tissue block is sectioned on a microtome and several sections are placed on the histologic slides (Fig. 3). These are then stained with hematoxylin and eosin (although other stains like toluidine blue are sometimes used) and coverslipped. Histologic slides are then examined under the microscope by the Mohs surgeon. Technique artifacts can happen if the steps are not adequately followed, including poor coloration, curled sections, slides without epidermis (not flattened enough) or subcutaneous tissue (insufficient freezing time), freezing artifacts, or tumor floaters (which are fragments of tumor tissue which have been displaced into tumor-free areas during flattening of the specimen).³⁵ In addition, errors can occur because of tissue that "drops out" during processing, improper mapping, and correlation, when surgeons do not appropriately excise sufficient potentially-normal tissue to ensure clearance of all tumor tissue and non-contiguous tumors.

If residual tumor is noted at the microscope (positive margins), the process is repeated. A new 1–2 mm margin is again taken only around the area compromised and mapped positively during microscopic evaluation. If only the deep margin is involved, the second stage can be taken in that area without enlarging the diameter of the defect. Careful handling is important to maintain orientation. In addition, it's important to take tissue fully around the mapped tumor positive area to limit the chance of sampling error of the second and subsequent stages.^{36,37} Once margins are tumor-free, the Mohs surgeon or multi-specialty colleagues can safely reconstruct the wound.

Variations on the surgical technique

1 – Incision degree angle: Some Mohs surgeons incise the skin with the blade angled at 90-degrees instead of the traditional 45-degree beveled angle. Although the 90-degree angle variation requires more laboratory work to flatten or "relax" the surgical specimen, it is an alternative as long as the entire surgical margin can be flattened to the same section plane.³⁸ A potential pitfall of this is "pushing through" tumor tissue or creating tissue gaps when making relaxing cuts. However, once the surgery is done, there is no need to de-bevel prior to reconstruction.

2 – Methods for flattening, freezing, and embedding the specimen: Options include *in vivo* intraoperative relaxing incisions, heat extractor flattening at the cryostat, freezing on a glass slide, the Miami Special technique, cryomold, the Cryo-EmbedderTM, and the Rio de Janeiro technique.^{39–43} Regardless of the chosen method, the main objective is to prepare high-quality slides.




Figure 3 Surgical Technique. (A), Clinically evident tumor is removed (debulking) by saucerization. (B), First stage margins are removed at a 45-degree angle. (C), Surgical specimen flattened (lateral margins are on the same plane as the deep margin) and colored with different dyes for orientation. (D), Surgical specimen frozen on a metal plate. (E-F) A specific gel called Optimum Cutting Temperature (OCT) is added to the metal plate to create the tissue block. (G), Tissue block ready for sectioning. (H), The tissue block is sectioned on a microtome and several sections are placed on the histologic slides. Slides are then stained and coverslipped (not shown in the figure) before microscopic examination.

3 – Staining variations: Instead of hematoxylin and eosin, some Mohs surgeons use toluidine blue.⁴⁴ When using toluidine blue, the typical finding is metachromasia defined as a magenta hue, which typically surrounds BCC nests.⁴⁵ In SCC, this finding tends to be less intense.⁴⁶

Wide local excision compared to MMS

Wide Local Excisional (WLE) specimens sent to the pathology laboratory for evaluation of margins are processed in a cross-

sectional or “bread-loaf” manner. Representative tissue is sliced vertically at 2- to 4-mm intervals to check for tumor presence at the surgical margin.⁶ The amount of tissue analysed depends on the number of sections obtained. Typically, less than 1% to 2% of the specimen margin is evaluated. Sampling error will occur if the intervals of the sections miss extensions of the tumor, which may penetrate between the sampled sections.^{5,7} Figs. 1 and 2 compare the histologic evaluation of WLE versus MMS.

It is extremely important to mention that WLE with frozen section analysis is not the same procedure as MMS. In WLE with frozen section analysis, the evaluation of margins follows the same process as the traditional WLE (bread-loaf technique) so tumor compromised margins may be missed.⁶

The Tubingen Torte Technique, the Munich Method, and excision with *en face* margin analysis also differ from MMS. Tubingen Torte Technique is performed on paraffin-embedded sections and separates the lateral margins from the deep margins for histopathological analysis.⁴⁷ During histologic sectioning, the external lateral margins are sectioned on the same plane and the deep margins from the bottom up.⁴⁸ In the Munich method, there is no debulking; the lateral and deep margins are not flattened into one plane before sectioning and the excision margins are perpendicular to the skin surface.⁴⁹ Horizontal sections are obtained in the cryostat (every 150 microns) from the bottom up to the epidermis surface.⁵⁰ Excision with *en face* margin analysis is similar to the Munich method, but the tissue is sectioned from the epidermis to the bottom and the deep margin may not be fully evaluated.^{51,52} These methods aim to achieve a complete circumferential peripheral and deep margin assessment but are outside the scope of this article. Detailed descriptions of each method have been published.⁴⁷⁻⁵² As with any procedure, clearance and recurrence rates of these techniques may be dependent on the training and experience of the provider and proper tumor selection for the appropriate treatment technique. However, the ability of 100% deep and peripheral tumor margin assessment by the same doctor acting as surgeon and pathologist at the same time allows for the highest published cure rates and accurate clinicopathologic correlation in real-time.

Indications of MMS

The indications of MMS follow the Appropriate Use Criteria (AUC) guidelines created by the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and American Society for Mohs Surgery to help clinicians select the most appropriate neoplasms for treatment with MMS.^{2,53,54} In 2016, a Brazilian guideline was written with similar recommendations.¹⁵

Based on the characteristics of an individual tumor, anatomic location (Fig. 4), and unique patient characteristics, the tumor is considered a low or high-risk tumor. Basically, the high-risk BCC, high-risk SCC, and the rare NMSC (DFSP, mucinous carcinoma, etc.) should be referred for MMS (Fig. 5); as well as Melanoma In Situ (MIS) in high-risk areas.^{2,5,15,53,54} Invasive melanomas are increasingly being treated with MMS demonstrating cure rates comparable to and often better than WLE.^{55,56}

MMS safety

MMS is traditionally performed under local anesthesia. In the United States, where the technique is performed frequently, only on rare occasions MMS is performed under conscious sedation or general anesthesia.⁵⁷⁻⁵⁹ Local anesthesia is the safest method for the patient because MMS




Figure 4 Anatomic risk areas. Red: High-risk areas. central face, eyelids, eyebrows, periorbital skin, nose, lips, chin, mandible, preauricular and postauricular skin, temple area, ear, genitalia, hands, and feet. Yellow: Medium-risk areas. cheeks, forehead, scalp, neck, and pretibial. Green: Low-risk areas. Trunk and extremities (excluding hands, feet, nail units, pretibial area, and ankles).

can take several hours.^{5,57,60-62} Measures to minimize discomfort of local anesthesia should be taken. Overall, MMS is considered a safe procedure due to the local anesthesia and avoidance of the risks of general anesthesia. Patients that may be considered "poor surgical candidates" for the operating room with general anesthesia are typically able to undergo MMS. A large 23-center prospective study evaluated Adverse Events (AE) associated with MMS surgery. Minor postoperative complications and serious AE were reported in 0.72% and 0.02% of cases, respectively. The most common complications included infections, bleeding, or impaired wound healing. Only 4 of 20,821 cases studied required admission to the hospital, constituting 2.7% of all adverse events and 0.02% of all procedures, and there were no cases of permanent disability or death. Among patients that were hospitalized, no cases happened during surgery, all were in the postoperative period due to local infection, and all were treated with intravenous antibiotics. None of the hospitalized patients had life-threatening events or death.⁵⁷ Other similar studies disclosed no serious complications after cutaneous surgery that required hospitalization.⁶⁰

In a study with 3,937 patients comparing major complications from MMS performed in office-based versus hospital-based settings the results showed that procedures were equally safe in both settings. The authors empha-

Parameters Basal cell carcinoma	Low risk tumor	High risk tumor
Clinical		
Location*/size	Area L < 20 mm	Area L ≥ 20mm
	Area M < 10 mm	Area M ≥ 10mm Area H**
Borders	Well defined	Poorly defined
Primary vs recurrent	Primary	Recurrent
Immunosuppression	No	Yes
Site of prior radiation therapy	No	Yes
Pathologic		
Growth pattern	Nodular, superficial#	Aggressive##
Perineural involvement	No	Yes
Parameters Squamous cell carcinoma		
Clinical		
Location*/size	Area L < 20 mm	Area L ≥ 20mm
	Area M < 10 mm	Area M ≥ 10mm Area H**
Borders	Well defined	Poorly defined
Primary vs recurrent	Primary	Recurrent
Immunosuppression	No	Yes
Site of prior radiation therapy or chronic inflammatory process	No	Yes
Rapidly growing tumor	No	Yes
Neurologic symptoms	No	Yes
Pathologic		
Degree of differentiation	Well to moderately differentiated	Poorly differentiated
High-risk histologic subtype###	No	Yes
Depth (thickness or Clark level)	<2 mm, or I, II, III	≥ 2mm ou IV, V
Perineural, lymphatic, or vascular involvement	No	Yes



Figure 5 Mohs micrographic indications for BCC and SCC. (*) For further details of risk areas, check Fig. 4. (**) Area H constitutes high-risk based on location, independent of size. (#) Other low-risk growth patterns include keratotic, infundibulocystic, and fibroepithelioma of Pinkus. (##) Having morpheaform, basosquamous (metatypical), sclerosing, mixed infiltrative, or micronodular features in any portion of the tumor. (###) Acantholytic and desmoplastic subtypes.

sized that dermatologic surgeons may continue to routinely perform these procedures in an outpatient office-based setting.⁶³

Most complications following MMS surgery are managed by Mohs surgeons in their offices, minimizing the need for utilization of additional health care resources.^{22,57,60,64} This is important in times when personal protective equipment and hospital beds are scarce and rationed, such as during international pandemics like COVID-19.

The majority of tumors treated with MMS are removed in one or two stages and are repaired with primary closure, which is associated with fewer complications and less postoperative pain compared with other repairs.⁶⁰ Patients, in general, have low peak pain levels following MMS and reconstruction and are highly satisfied with their pain control.^{22,60,64}

MMS efficacy

Table 1 demonstrates MMS efficacy for different cutaneous malignancies.^{1,3,65-85}

Tissue sparing with MMS

Conservation of healthy tissue has always been a matter of interest in skin cancer surgery. MMS has been shown in multiple studies to be tissue-sparing when compared to standard excision.⁸⁶ A recent study with infiltrative BCCs demonstrated that MMS saved 46% of healthy tissue when

compared to standard surgery.⁸⁷ Another study demonstrated significant preservation of healthy tissue (56%–86%) for facial BCCs near free margins when compared to the recommended standard excisional margins.⁸⁸ Similarly, Gnidecki et al., showed that MMS leads to respectively 43% and 45% smaller defects compared to standard excisions of primary BCC (4-mm margins) and high-risk, recurrent BCC (6-mm margins).⁸⁹ A small randomized trial for nodular BCCs <1 cm reported that defect size after MMS was significantly smaller ($p < 0.001$) than after standard excision (116.6 vs. 187.7 mm²).^{86,88}

Basal cell carcinoma

BCC is the most common human malignancy.² Although it rarely causes major complications, such as metastasis or death, BCC can be locally destructive invading deeper tissues such as muscle, cartilage, and bone.⁹⁰ The most common features associated with significant subclinical extensions are high-risk location, recurrent tumor, aggressive subtype, and tumor size >10mm.^{91,92} A recent study that evaluated margins (in mm) required for primary BCC clearance showed that the most significant factors related to larger margins were superficial, micronodular, infiltrative, and morpheaform subtypes; whereas clinically well-defined tumors were associated with smaller margins.⁹³

The most clinically relevant stratification to guide the management of patients with BCC is the differentiation between low-risk versus high-risk tumors for recurrence

Table 1 Comparison of cure rates after 5-years for different cutaneous malignancies treated with Mohs surgery or wide local excision.

Tumor	Cure rates (%)	
	Mohs micrographic surgery	Wide local excision
Basal cell carcinoma ^{1,3,65}	99 (primary) 90–93 (recurrent)	87–96 (primary) 83 (recurrent)
Squamous carcinoma ^{65–67}	92–99 (primary) 90 (recurrent)	92–95 (primary) 76 (recurrent)
Melanoma in situ ^{68,69}	98	83–85
<i>Dermatofibrosarcoma protuberans</i> ^{70,71}	98–100	80–88
Atypical fibroxanthoma ⁷⁶	98	91
Microcystic adnexal carcinoma ⁷²	94–96	40–83
Sebaceous carcinoma ^{72–75}	94	64–89
Extramammary Paget disease ⁷⁷	92	78

Adapted from: Tolkachjov SN et al., 2017.⁵

Other tumors such as leiomyosarcoma, melanoma, hidradenocarcinoma, Merkel cell carcinoma, mucinous carcinoma, and porocarcinoma have shown higher cure rates with the use of MMS.^{78–85}

(Fig. 5).⁵³ MMS has been shown to have superior cure rates in primary and recurrent BCCs.^{1,3} The recurrence rates are outlined in Table 1. It is also an efficient and cost-effective procedure as the treatment of choice for high-risk BCCs and those in cosmetically sensitive locations.^{5,15,94}

Squamous cell carcinoma

SCC is the second most common form of skin cancer. Similarly to BCC, SCC is increasing in incidence throughout the world.⁵⁴ They are typically graded as well-, moderately-, or poorly-differentiated neoplasms. Unlike BCCs, SCCs have significant metastatic potential.^{2,54,95} A 10-year retrospective cohort study showed that patients with SCC had a 3.7% incidence of metastasis and 2.1% risk of disease-specific death.⁹⁶ In the US, aggressive or high-risk SCCs are estimated to result in approximately 8,000 cases of lymph node (LN) metastases and 3,000 deaths each year.⁹⁵ As with BCC, published risk factors like tumor location and patient immunosuppression due to hematologic malignancies, immunosuppressive medications, organ transplantation, or genetic or acquired immunosuppressive diseases like Human Immunodeficiency Virus (HIV) are also associated with higher recurrence and metastatic rates, and these patients are most likely to benefit from MMS for SCC.⁹⁷ Multivariate analysis of tumor characteristics found that 5-high-risk factors were statistically independent prognostic factors: poor differentiation, perineural invasion, tumor diameter >2 cm, invasion of subcutaneous fat and ear, temple, or genital location.⁹⁶ Brigham and Women's Hospital (BWH) uses 4 of these high-risk factors (poor differentiation, perineural invasion, tumor diameter >2 cm, and subcutaneous fat invasion) to create a staging system, where: T0 is in situ SCC; T1 – zero risk factors; T2a – 1 risk factor; T2b – 2–3 risk factors; T3 – 4 risk factors or bone invasion.⁹⁶

It cannot be overemphasized that the best chance for SCC cure is in the complete surgical removal of the initial lesion, as all tumor treatment options are less successful

for persistent or recurrent tumors than for primary tumors. Once an SCC has recurred, the risk of spread to regional LN and distant metastases increases significantly. High-risk tumors (Fig. 5) are best treated with MMS.

In a cohort study, 647 patients treated with MMS alone for high-risk SCC, there were 19 local recurrences (2.9%), 31 nodal metastases (4.8%), 7 distant metastases (1.1%), and 7 disease-specific deaths (1.1%). They experienced the lowest rates of local recurrence, nodal metastasis, and disease-specific death published thus far for high-risk SCC.⁹⁸

SCCs with a single high-risk feature have a low risk for metastasis and death but an increased risk of local recurrence. A recent study comparing outcomes for these intermediate-risk tumors, BWH T2a, found that MMS provided improved outcomes when compared to WLE with permanent sections.⁹⁹

Treatment of SCC with MMS has shown superior cure rates than WLE, and local recurrences occur less frequently when SCC is treated by MMS, demonstrating to be a highly effective modality in the treatment of these tumors.^{5,98}

Melanoma in situ

Although MMS has been increasingly used for invasive melanomas in the US, we will limit our discussion to MIS. The initial studies of the successful use of MMS for primary cutaneous melanoma date from the late 90s. At the time, surgical specimens were performed with H&E stain.⁶⁸ Immunohistochemistry (IHC) using the melanoma antigen recognized by T cells-1 (MART-1) has been used now for many years and has increased the accuracy of margin examination with the frozen section processing of MMS and is the recommended method for those who treat melanomas with MMS.¹⁰⁰ Other stains like MITF and Sox10 have also been used, and others are being studied.

In a prospectively study of 1,120 MIS (1,072 patients) treated with MMS 3 patients (0.3%) had local recurrence and 3 had distant metastases. In all, 86% of MIS were successfully excised with a 6-mm margin; and 98.9% with 9-mm.¹⁰¹

In Brazil, the cost of MART-1 limits the use of MMS to treat MIS.

Dermatofibrosarcoma protuberans

DFSP is a rare fibroblastic tumor with a slow infiltrative growth that rarely metastasizes.¹⁰² DFSP is known for its extensive subclinical spread, therefore meticulous margin control is recommended.¹⁰² For WLE, recommended margins are 3-cm whereas MMS initial margins are at least 1-cm.¹⁰³ One of the first studies using MMS for DFSP reported no recurrence after an average follow-up of 3.4 years in a series of 20 cases.¹⁰⁴

A more recent study with long-term follow-up comparing WLE versus MMS demonstrated a recurrence rate of 30.8% and 3%, respectively. Furthermore, although preoperative tumor sizes were similar, MMS resulted in smaller defects allowing more primary closure (73%), whereas tumors treated with WLE required flaps or grafts in 52% of cases.¹⁰⁵

Ideally, MMS for DFSP should be performed with the IHC marker CD34 to better detect tumor cells, especially in recurrent cases where it may be difficult to distinguish scar from tumoral tissue.^{102,103} When available, MMS (or another method of complete histologic margin control) is the recommended treatment for DFSP due to its higher cure rates and reduced morbidity.¹⁰⁵

Microcystic adnexal carcinoma

Microcystic Adnexal Carcinoma (MAC) is a sclerotic sweat gland carcinoma that presents as a slow-growing indurated and often hypopigmented plaque on the head and neck. It affects sun-exposed areas of older adults, usually Caucasians.^{72,106} MMS has become an important indication for MAC because of its likelihood of subclinical extension.¹⁰⁷ The local recurrence rate is between 17% and 60% with WLE and 4.7% to 5.7% with MMS.⁷²

Sebaceous carcinoma

Sebaceous carcinoma is derived from the adnexal epithelium of the sebaceous glands usually occurring in adults older than 60-years, on the eyelid, head and neck, and trunk. It is often seen as a pink to red-yellow papule or nodule that may bleed in a third of the cases.^{51,72}

A consensus of a panel of experts believes that margin control with MMS or other methods of complete circumferential peripheral and deep margin assessment are most likely to achieve tumor clearance and reduce the risk of recurrence.⁵¹ WLE recurrence rate is 11% to 36% after 5-years and an 18% to 30% 5-year mortality has been reported with WLE of 5- to 6-mm margins on periocular location.^{73,75} Although reporting bias may distort the data, the overall recurrence rate of sebaceous carcinoma treated with MMS is 6.4% (7/109) with a metastatic rate of 3.7% (4/109).⁷²

Atypical fibroxanthoma

Atypical Fibroxanthoma (AFX) is a fibrohistiocytic tumor with a relatively high local recurrence rate but low metastatic potential. Clinically, AFX typically presents as a pink nodule on the head and neck in elderly white men, growing over several months.⁷⁶

A systematic review of a pooled group of 907 patients with 914 tumors, demonstrated a lower recurrence rate with MMS than WLE (2.0% vs. 8.7%). Although the gap of the recurrence rate between MMS and WLE is narrow, we have to consider that 80% of AFX starts on the head and neck, hence, MMS emerges as the most suitable technique to ensure microscopically controlled excision while optimizing tissue sparing on anatomically sensitive areas.⁷⁶

Other cutaneous tumors

Almost all types of cutaneous malignancies have been treated through MMS over the decades, even the rare non-melanoma skin cancers, with superior results to WLE (Table 1).^{82,85} Although these tumors vary in the anatomical structure of origin, they all share one crucial aspect: they are contiguous tumors, often with subclinical extension underneath the skin surface, rendering a non-MMS surgeon's subjective measurement of the tumor margins less accurate than an MMS surgeon's ability to assess the complete peripheral and deep margins microscopically.⁵

Reconstruction after MMS

Reconstruction is only performed after margins are confirmed to be histologically tumor-free, ideally when the wound is freshly created rather than open or bandaged for an extended period of time prior to reconstruction.⁵ On the other hand, on excisional surgery, reconstructions are performed without knowing if the tumor was completely removed. This is the reason why NCCN does not recommend any kind of tissue rearrangement (flaps) after WLE; the flap may "hide" cancerous cells making recurrences catastrophic.¹⁰⁸ In the authors' experiences, same-day reconstruction with clear margins is preferred by patients undergoing cutaneous surgery.^{109,110}

Mohs surgeons must have the ability to perform a variety of techniques when closing both simple and more complex skin defects, including complex linear closures, skin flaps, and grafts. Even large flaps, interpolation flaps, and large grafts are safely performed in the office setting under local anesthesia.^{111–113} In the US, dermatologists represent the largest specialty group performing reconstructive surgeries, performing more than 4-times the number of local flaps and more than 6 times the number of grafts as plastic surgeons, meanwhile averaging a significantly larger number of average per-physician yearly cases than any other specialist group.^{114,115} In a minority and specific cases, a multidisciplinary approach with oculoplastics, plastic surgery, urology, and otolaryngology (ENT Surgeons) or head & neck oncology may be the best option for complicated cases.^{116,117} Figs. 6–9 illustrate MMS cases performed by the authors.




Figure 6 BCC with extensive subclinical extension. (A), Surgical margins of the first stage. (B), First stage margins based on dermoscopy, with fine telangiectasias and white red structureless areas. Although the figure shows many telangiectasias surrounding the first stage margin, these telangiectasias were interpreted as resulting from photodamage since they were widely distributed on his central face. After margins were clear, similar telangiectasias were still present surrounding the defect. (C), Histological section of the specimen obtained with Mohs surgery showing nests of basaloid cells adjacent to or connected to the epidermis, consistent with mixed basal cell carcinoma (Hematoxylin & eosin, $\times 40$). (D), Digital map of the first stage. White lines indicate the presence of residual tumor. (E), Surgical wound after 6 stages, with the involvement of the left nasal wall and medial malar region. (F), 2-months postoperatively. Cheek restored with primary closure and nasal sidewall with Burow full-thickness skin graft and second intention healing.



Figure 7 Ill-defined basal cell carcinoma on the right pre-auricular area. (A), Preoperative. (B), Dermoscopy showing arborizing vessels and shiny white, red structureless areas. (C), Histological section of Mohs surgery specimen demonstrated irregular nests of basaloid cells, consistent with infiltrative basal cell carcinoma (Hematoxylin & eosin $\times 25$). (D) Surgical wound after 2 stages. Advancement flap design. (E), Flap undermined. Note that M-plasty was not performed. (F), Immediate postoperative.

Final considerations

MMS is an effective treatment modality for numerous cutaneous malignancies. It has achieved statistically significant superiority to WLE for the treatment of BCC, SCC, and other cutaneous tumors. Dermatologists and non-dermatologists managing cutaneous malignancies must understand MMS indications so patients can have a higher cure rate avoiding future recurrences and complications associated with their treatment.

The future of MMS is likely to see an increased application for a variety of cutaneous malignancies and increased use of noninvasive imaging like Multispectral Optoacoustic Tomography, Optical Coherence Tomography to better

understand in vivo tumor characteristics.^{118,119} Ex vivo fluorescence confocal microscopy is a new imaging tool that offers an attractive alternative to conventional frozen histology for the evaluation of margins in freshly excised tissue although technical issues still prevent the wide use of this technique.¹²⁰ However, until concrete studies with long-term follow-up are performed, MMS with hematoxylin e eosin histologic evaluation will continue to be the mainstay treatment.

Financial support

None declared.



Figure 8 Squamous cell carcinoma on the left periorbital region. (A), Preoperative oblique view. (B), Bright whitish-yellow areas and arboriform telangiectasias. (C), Histological section of Mohs surgery specimen showing atypical keratinocytes and horn pearls, consistent with well-differentiated squamous cell carcinoma (Hematoxylin & eosin $\times 100$). (D), Rotation flap design. (E), Immediate postoperative. (F), 2-month postoperatively.




Figure 9 Dermatofibrosarcoma protuberans. (A), Tumor on the right infraclavicular region and first stage margins. (B), Dermoscopy showing thin and linear arboriform telangiectasias, shiny white streaks, pink amorphous area, surrounded by a pigmented network. (C) Histological section of Mohs surgery specimen showing a fusocellular proliferation in the dermis and subcutaneous tissue, consistent with dermatofibrosarcoma protuberans (Hematoxylin & eosin $\times 100$). Preoperative immunohistochemistry was positive for CD34. (D), Surgical margins mapped with different colors. (E), Surgical wound and primary closure design. (F), 1-month postoperatively. Erythema resolved over time.

Authors' contributions

Guilherme Canho Bittner: Participation in the conception and planning of the study; obtaining, analyzing, and interpreting the data; writing; approval of its final version.

Felipe Bochnia Cerci: Participation in the conception and planning of the study; analyzing, and interpreting the data; writing; critical review of the manuscript; approval of its final version.

Elisa Mayumi Kubo: Writing; approval of its final version.

Stanislav N. Tolkachjov: Obtaining analyzing and interpreting the data; critical review of the manuscript; approval of its final version.

Conflicts of interest

None declared.

References

1. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. *J Dermatol Surg Oncol.* 1989;15:315–28.
2. Mansouri B, Bicknell LM, Hill D, Walker GD, Fiala K, Housewright C. Mohs Micrographic Surgery for the Management of Cutaneous Malignancies. *Facial Plast Surg Clin North Am.* 2017;25:291–301.
3. Rowe DE, Carroll RJ, Day CL. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. *J Dermatol Surg Oncol.* 1989;15:424–31.
4. Tschetter AJ, Campoli MR, Zitelli JA, Brodland DG. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study. *J Am Acad Dermatol.* 2020;82:139–48.

5. Tolkachjov SN, Brodland DG, Coldiron BM, Fazio MJ, Hruza GJ, Roenigk RK, et al. Understanding Mohs Micrographic Surgery: A Review and Practical Guide for the Nondermatologist. *Mayo Clin Proc.* 2017;92:1261–71.
6. Dim-Jamora KC, Perone JB. Management of Cutaneous Tumors with Mohs Micrographic Surgery. *Semin Plast Surg.* 2008;22:247–56.
7. Kimyai-Asadi A, Goldberg LH, Jih MH. Accuracy of serial transverse cross-sections in detecting residual basal cell carcinoma at the surgical margins of an elliptical excision specimen. *J Am Acad Dermatol.* 2005;53:469–74.
8. Bologna J, Schaffer JV, Cerroni L. *Dermatology.* 4th ed. USA: Elsevier; 2018.
9. Mohs FE. Chemosurgery: a microscopically controlled method of cancer excision. *Arch Surg.* 1941;42:279–95.
10. Tromovitch TA, Stegeman SJ. Microscopically Controlled Excision of Skin Tumors: Chemosurgery (Mohs): Fresh Tissue Technique. *Archiv Dermatol.* 1974;110:231–2.
11. de Eusebio Murillo E, Martin Fuentes A, Ruiz-Salas V, Garcés JR, Medrano RM, López-Esteban JL, et al. Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015. *Actas Dermosifiliogr.* 2017;108:836–43.
12. du Plessis PJ, Leventer M, Krekels G, de Wet JD, Laeuchli S. Outcomes of Mohs Micrographic Surgery at the American Society for Dermatologic Surgery International Traveling Mentorship Program International Mohs Fellowship Recognition Units: A Retrospective Survey of 5889 Cases From South Africa, Romania, and the Netherlands. *Dermatol Surg.* 2019;45:1515–62.
13. Smeets NW, Kuijpers DI, Nelemans P, Ostrertrag JU, Verhaegh MEJM, Krekels GAM, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face—results of a retrospective study and review of the literature. *Br J Dermatol.* 2004;151:141–7.
14. Stewart TJ, Moreno Bonilla G, Venning VL, Lee S, Fernandez-Penas P. Mohs Micrographic Surgery at the Skin and Cancer Foundation Australia, 20 Years Later (1997-2017). *Dermatol Surg.* 2020;46:165–8.
15. Cernea SS, Gontijo G, Pimentel ER, Tarlé RG, Ferreira JASL, Fernandes VMC, et al. Indication guidelines for Mohs micrographic surgery in skin tumors. *An Bras Dermatol.* 2016;91:621–7.
16. sbd.org [Internet]. Cirurgia micrográfica de Mohs: Conceito, normas técnicas para realização, critérios para formação e capacitação do cirurgião micrográfico pela Sociedade Brasileira de Dermatologia (SBD) [Acesso em 24 jun. 2020]. Disponível em: <<http://www.sbd.org.br/mm/cms/2019/06/04/cirurgia-micrograficacriterios.pdf>>.
17. abderm.org [Internet]. MDS Subspecialty Certification Exam Study Guide and FAQs [Acesso em 25 jun. 2020]. Disponível em: <<https://www.abderm.org/public/announcements/mds-subspecialty-certification-exam-study-guide-and-faqs.aspx>>.
18. Wright TI, Baddour LM, Barbari EF, Roenigk RK, Philips PK, Jacobs MA, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. *J Am Acad Dermatol.* 2008;59:464–73.
19. Soleymani T, Brodland DG, Zitelli JA. A retrospective case series evaluating the efficacy of pre-operative, intra-incisional antibiotic prophylaxis in Mohs micrographic surgery: an effective method to reduce surgical site infections and minimize systemic antibiotic use. *J Am Acad Dermatol.* 2020;83:1501–3.
20. Levin EC, Chow C, Makhzoumi Z, Jin C, Shiboski SC, Arron ST. Association of Postoperative Antibiotics With Surgical Site Infection in Mohs Micrographic Surgery. *Dermatol Surg.* 2019;45:52–7.
21. Huether MJ, Griego RD, Brodland DG, Zitelli JA. Clindamycin for intra-incisional antibiotic prophylaxis in dermatologic surgery. *Arch Dermatol.* 2002;138:1145–8.
22. Kreicher KL, Bordeaux JS. Addressing Practice Gaps in Cutaneous Surgery: Advances in Diagnosis and Treatment. *JAMA Facial Plast Surg.* 2017;19:147–54.
23. Taylor O, Carr C, Greif C, Garcia A, Tran S, Srivastava D, et al. Postoperative Bleeding Complications Associated with Blood Thinning Agents during Mohs Micrographic Surgery: A Retrospective Cohort Study. *J Am Acad Dermatol.* 2021;84:225–7.
24. Cook-Norris RH, Michaels JD, Weaver AL, Philips PK, Brewer JD, Roenigk RK, et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. *J Am Acad Dermatol.* 2011;65:584–91.
25. Alcalay J, Alcalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? *Dermatol Surg.* 2004;30:1091–4.
26. Chang TW, Arpey CJ, Baum CL, Brewer JD, Hochwalt PC, Hocker TL, et al. Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery. *Dermatol Surg.* 2015;41:784–93.
27. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. *J Am Acad Dermatol.* 2003;48:233–7.
28. Matzke TJ, Christenson LJ, Christenson SD, Atanashova N, Otley CC. Pacemakers and implantable cardiac defibrillators in dermatologic surgery. *Dermatol Surg.* 2006;32:1155–62.
29. Weyer C, Siegle RJ, Eng GG. Investigation of hyfrecators and their in vitro interference with implantable cardiac devices. *Dermatol Surg.* 2012;38:1843–8.
30. Amin SD, Homan KB, Assar M, Lee M, Housewright CD. Hyfrecation and Interference With Implantable Cardiac Devices. *Dermatol Surg.* 2020;46:612–5.
31. Tripathi SV, Hurst EA. Pacemakers, Deep Brain Stimulators, Cochlear Implants, and Nerve Stimulators: A Review of Common Devices Encountered in the Dermatologic Surgery Patient. *Dermatol Surg.* 2019;45:1228–36.
32. Chen P, Smith H, Vinciullo C. Bupivacaine as an Adjunct to Lidocaine in Mohs Micrographic Surgery: A Prospective Randomized Controlled Trial. *Dermatol Surg.* 2018;44:607–10.
33. Kantor J. Fully digital Mohs map for micrographic surgery. *J Am Acad Dermatol.* 2018;78:e65–6.
34. Alcalay J. Mohs Mapping in the Cloud: An Innovative Method for Mapping Tissue in Mohs Surgery. *J Drugs Dermatol.* 2015;14:1127–30.
35. Bouzari N, Olbricht S. Histologic pitfalls in the Mohs technique. *Dermatol Clin.* 2011;29:261–72.
36. Cartee TV, Monheit GD. How many sections are required to clear a tumor? Results from a web-based survey of margin thresholds in Mohs micrographic surgery. *Dermatol Surg.* 2013;39:179–86.
37. Zabielski M, Leithauer L, Godsey T, Gloster HM Jr. Laboratory errors leading to nonmelanoma skin cancer recurrence after Mohs micrographic surgery. *Dermatol Surg.* 2015;41:913–6.
38. Davis DA, Pellowski DM, William Hanke C. Preparation of frozen sections. *Dermatol Surg.* 2004;30:1479–85.
39. Wanitphakdeedecha R, Nguyen TH, Chen TM. In vivo intra-operative relaxing incisions for tissue flattening in Mohs micrographic surgery. *Dermatol Surg.* 2008;34:1085–7.
40. Sanchez FH, Ribeiro JF, Russo AC. Validation of a new technique to freezing and embedding tissue in Mohs surgery, using an animal model. *Acta Cir Bras.* 2016;31:533–41.
41. Nouri K, O'Connell C, Alonso J, Rivas MP, Alonso Y. The Miami Special: a simple tool for quality section mounting in Mohs surgery. *J Drugs Dermatol.* 2004;3:175–7.

42. Leshin B, Cook SR, Frye DW. Cryomold: a device for tissue embedding in Mohs micrographic surgery. *J Dermatol Surg Oncol.* 1991;17:234-6.
43. Lear WP, Anderson NL, Akeroyd JE, Berg DJDS. A Comparison of Four Mohs Tissue Preparation Methods Using Porcine Skin. *Dermatol Surg.* 2010;36:1419-25.
44. Humphreys TR. Commentary: Does the use of toluidine blue and hematoxylin and eosin improve tumor detection by Mohs surgery trainees? *Dermatol Surg.* 2013;39:1001-2.
45. Humphreys TR, Nemeth A, McCrevey S, Baer SC, Goldberg LH. A pilot study comparing toluidine blue and hematoxylin and eosin staining of basal cell and squamous cell carcinoma during Mohs surgery. *Dermatol Surg.* 1996;22:693-7.
46. Trieu D, Drosou A, Goldberg LH, Kimyai-Asadi A. Detecting spindle cell squamous cell carcinomas with toluidine blue on frozen sections. *Dermatol Surg.* 2014;40:1259-60.
47. Leigh M, Zavattaro E, Bellinzona F, Furlan G, Leigh G. Micrographic surgery (Tubingen torte technique) for the treatment of an invasive dermatofibrosarcoma protuberans with muscular involvement. *G Ital Dermatol Venereol.* 2010;145:309-11.
48. Kopke LF, Konz B. Micrographic surgery. A current methodological assessment. *Hautarzt.* 1995;46:607-14.
49. Boztepe G, Hohenleutner S, Landthaler M, Hohenleutner U. Munich method of micrographic surgery for basal cell carcinomas: 5-year recurrence rates with life-table analysis. *Acta Derm Venereol.* 2004;84:218-22.
50. Kopke LF, Konz B. Micrographic surgery is synonym of Mohs surgery? *An Bras Dermatol.* 1994;69:499-502.
51. Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, et al. Sebaceous carcinoma: evidence-based clinical practice guidelines. *Lancet Oncol.* 2019;20:e699-714.
52. Nizamoglu M, Douglas H, McArdle C, Mathew B, Vize C, Matteucci P. Using frozen section margin control technique to manage non-melanomatous skin lesions in high-risk sites. *J Plast Reconstr Aesthet Surg.* 2016;69:657-62.
53. Work G, Invited R, Kim JYS, Koslow JH, Mittal B, Moyer J, et al. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol.* 2018;78:540-59.
54. Work G, Reviewers I, Kim JYS, Hoslow JH, Mittal B, Moyer J, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. *J Am Acad Dermatol.* 2018;78:560-78.
55. Etzkorn JR, Sobanko JF, Elenitsas R, Neman JG, Goldbach H, Shin TM, et al. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. *J Am Acad Dermatol.* 2015;72:840-50.
56. Ellison PM, Zitelli JA, Brodland DG. Mohs micrographic surgery for melanoma: A prospective multicenter study. *J Am Acad Dermatol.* 2019;81:767-74.
57. Alam M, Ibrahim O, Nodzinski M, Strasswimmer JM, Jiang SIB, Cohen JL, et al. Adverse events associated with Mohs micrographic surgery: multicenter prospective cohort study of 20,821 cases at 23 centers. *JAMA Dermatol.* 2013;149:1378-85.
58. Feng H, Feng PW, Geronemus RG. Diversity in the US Mohs Micrographic Surgery Workforce. *Dermatol Surg.* 2020;46:1451-5.
59. Albertini JG, Wang P, Fahim C, Hufless S, Stasko T, Vidimos AT, et al. Evaluation of a Peer-to-Peer Data Transparency Intervention for Mohs Micrographic Surgery Overuse. *JAMA Dermatol.* 2019;155:906-13.
60. Merritt BG, Lee NY, Brodland DG, Zitelli JA, Cook J. The safety of Mohs surgery: a prospective multicenter cohort study. *J Am Acad Dermatol.* 2012;67:1302-9.
61. Locke MC, Davis JC, Brothers RJ, Love WE. Assessing the outcomes, risks, and costs of local versus general anesthesia: A review with implications for cutaneous surgery. *J Am Acad Dermatol.* 2018;78:983-8.
62. Alam M, Schaeffer MR, Geisler A, Poon E, Fosko SW, Srivastava D. Safety of Local Intracutaneous Lidocaine Anesthesia Used by Dermatologic Surgeons for Skin Cancer Excision and Postcancer Reconstruction: Quantification of Standard Injection Volumes and Adverse Event Rates. *Dermatol Surg.* 2016;42:1320-4.
63. Kimyai-Asadi A, Goldberg LH, Peterson SR, Silapint S, Jih MH. The incidence of major complications from Mohs micrographic surgery performed in office-based and hospital-based settings. *J Am Acad Dermatol.* 2005;53:628-34.
64. Hussain W, Affleck A, Al-Niimi F, Cooper A, Craythorne E, Fleming C, et al. Safety, complications and patients' acceptance of Mohs micrographic surgery under local anaesthesia: results from the U.K. MAPS (Mohs Acceptance and Patient Safety) Collaboration Group. *Br J Dermatol.* 2017;176:806-8.
65. Staub G, Revol M, May P, Bayol JC, Verola O, Servant JM. Excision skin margin and recurrence rate of skin cancer: a prospective study of 844 cases. *Ann Chir Plast Esthet.* 2008;53:389-98.
66. Roenigk RK, Roenigk HH Jr. Current surgical management of skin cancer in dermatology. *J Dermatol Surg Oncol.* 1990;16:136-51.
67. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. *J Am Acad Dermatol.* 1992;26:976-90.
68. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. *J Am Acad Dermatol.* 1997;37:236-45.
69. Zitelli JA. Surgical margins for lentigo maligna, 2004. *Arch Dermatol.* 2004;140:607-8.
70. Hancox JG, Kelley B, Greenway HT Jr. Treatment of dermatofibroma sarcoma protuberans using modified Mohs micrographic surgery: no recurrences and smaller defects. *Dermatol Surg.* 2008;34:780-4.
71. Brewer JD, Roenigk RK, Otley CC. Wide local excision or Mohs micrographic surgery for primary dermatofibrosarcoma protuberans. *Am J Clin Oncol.* 2011;34:545-6.
72. Tolkachjov SN. Adnexal Carcinomas Treated With Mohs Micrographic Surgery: A Comprehensive Review. *Dermatol Surg.* 2017;43:1199-207.
73. Chang AY, Miller CJ, Elenitsas R, Newman JG, Sobanko JF. Management Considerations in Extraocular Sebaceous Carcinoma. *Dermatol Surg.* 2016;42 Suppl 1:S57-65.
74. Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. *Dermatol Surg.* 2014;40:241-6.
75. Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. *J Am Acad Dermatol.* 2001;44:1004-9.
76. Tolkachjov SN, Kelley BF, Alahdab F, Erwin PJ, Brewer JD. Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision. *J Am Acad Dermatol.* 2018;79:929-34.
77. O'Connor WJ, Lim KK, Zalla MJ, Gagnon M, Otley CC, Nguyen TH, et al. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget's disease. *Dermatol Surg.* 2003;29:723-7.
78. Humphreys TR, Finkelstein DH, Lee JB. Superficial leiomyosarcoma treated with Mohs micrographic surgery. *Dermatol Surg.* 2004;30:108-12.

79. Winchester DS, Hocker TL, Brewer JD, Baum CL, Hochwalt PC, Arpey CJ, et al. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. *J Am Acad Dermatol.* 2014;71:919–25.
80. Valentin-Nogueras SM, Brodland DG, Zitelli JA, Gonzalez-Sepulveda L, Nazario CM. Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ. *Dermatol Surg.* 2016;42:733–74.
81. DeBloom JR 2nd, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. *Dermatol Surg.* 2010;36:1251–7.
82. Tolkachjov SN, Hocker TL, Hochwalt PC, Camileri MJ, Arpey CJ, Brewer JD, et al. Mohs micrographic surgery for the treatment of hidradenocarcinoma: the Mayo Clinic experience from 1993 to 2013. *Dermatol Surg.* 2015;41:226–31.
83. Kline L, Coldiron B. Mohs Micrographic Surgery for the Treatment of Merkel Cell Carcinoma. *Dermatol Surg.* 2016;42:945–51.
84. Adefusika JA, Pimentel JD, Chavan RN, Brewer JD. Primary mucinous carcinoma of the skin: the Mayo Clinic experience over the past 2 decades. *Dermatol Surg.* 2015;41:201–8.
85. Tolkachjov SN, Hocker TL, Camilleri MJ, Baum CL. Treatment of Porocarcinoma With Mohs Micrographic Surgery: The Mayo Clinic Experience. *Dermatol Surg.* 2016;42:745–50.
86. Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. *Dermatol Surg.* 2009;35:1349–54.
87. van Kester MS, Goeman JJ, Genders RE. Tissue-sparing properties of Mohs micrographic surgery for infiltrative basal cell carcinoma. *J Am Acad Dermatol.* 2019;80:1700–3.
88. Terzian LR, Nogueira VMA, Paschoal FM, Barros JC, Filho CASM. Mohs Micrographic Surgery for tissue preservation in facial oncologic surgery. *Surg Cosmet Dermatol.* 2010;2:257–63.
89. Gniadecki R, Glud M, Mortensen K, Bang B, Biskup E, Omland SH. Favourable results of Mohs micrographic surgery for basal cell carcinoma. *Dan Med J.* 2015;62:A5171.
90. Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Factors Predictive of Recurrence, Metastasis, and Death from Primary Basal Cell Carcinoma 2cm or Larger in Diameter. *J Am Acad Dermatol.* 2020;83:832–8.
91. Hoorens I, Batteauw A, Van Maele G, Lapiere K, Boone B, Onge-nae K. Mohs micrographic surgery for basal cell carcinoma: evaluation of the indication criteria and predictive factors for extensive subclinical spread. *Br J Dermatol.* 2016;174:847–52.
92. Flohil SC, van Dorst AM, Nijsten T, Martino Neumann HA, Munte K. Mohs micrographic surgery for basal cell carcinomas: appropriateness of 'Rotterdam' criteria and predictive factors for three or more stages. *J Eur Acad Dermatol Venereol.* 2013;27:1228–35.
93. Cerci FB, Kubo EM, Werner B, Tolkachjov SN. Surgical margins required for basal cell carcinomas treated with Mohs micrographic surgery based on tumor features. *J Am Acad Dermatol.* 2020;83:493–500.
94. Kauvar AN, Cronin T Jr, Roenigk R, Hruza G, Bennett R. American Society for Dermatologic S. Consensus for non-melanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. *Dermatol Surg.* 2015;41:550–71.
95. Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for Nonmelanoma Skin Cancer Treatment, Part II: Squamous Cell Carcinoma, Including a Cost Analysis of Treatment Methods. *Dermatol Surg.* 2015;41:1214–40.
96. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. *JAMA Dermatol.* 2013;149:541–7.
97. Skulsky SL, O'Sullivan B, McArdle O, Leader M, Roche M, Conlon PJ, et al. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. *Head Neck.* 2017;39:578–94.
98. Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. *J Am Acad Dermatol.* 2019;80:633–8.
99. Xiong DD, Beal BT, Varra V, Rodriguez M, Cundall H, Woody NM, et al. Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision. *J Am Acad Dermatol.* 2020;82:1195–204.
100. Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. *Dermatol Surg.* 2002;28:656–65.
101. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. *J Am Acad Dermatol.* 2012;66:438–44.
102. Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe G, Breuninger H, Bauer S, et al. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018. *J Dtsch Dermatol Ges.* 2019;17:663–8.
103. Saiag P, Grob JJ, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. *Eur J Cancer.* 2015;51:2604–8.
104. Parker TL, Zitelli JA. Surgical margins for excision of dermatofibrosarcoma protuberans. *J Am Acad Dermatol.* 1995;32:233–6.
105. Lowe GC, Onajin O, Baum CL, Otley CC, Arpey CJ, Roenigk RK, et al. A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience. *Dermatol Surg.* 2017;43:98–106.
106. Worley B, Owen JL, Barker CA, Behshad R, Bichakjian CK, Bolotin D, et al. Evidence-Based Clinical Practice Guidelines for Microcystic Adnexal Carcinoma: Informed by a Systematic Review. *JAMA Dermatol.* 2019;155(9):1059–68.
107. King BJ, Tolkachjov SN, Winchester DS, Baum CL, Brewer JD, Arpey CJ, et al. Demographics and outcomes of microcystic adnexal carcinoma. *J Am Acad Dermatol.* 2018;79:756–8.
108. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, et al. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2016;14:574–97.
109. Egeler SA, Johnson AR, Ibrahim AMS, Bucknor A, Chen A, Malyar M, et al. Reconstruction of Mohs Defects Located in the Head and Neck. *J Craniofac Surg.* 2019;30:412–7.
110. Kohli N, Kwedar K, Golda N. Combined closures in reconstructive surgery. *Dermatol Online J.* 2017;23, 13030/qt6dx2m7cf.
111. Schmitt A, DePry J, Tsai S, Bordeaux J. Retrospective Evaluation of the Safety of Large Skin Flap, Large Skin Graft, and Interpolation Flap Surgery in the Outpatient Setting. *Dermatol Surg.* 2018;44:1537–46.
112. Tolkachjov SN. The "Combo-Z" variable tissue movement flap for repair of multiple adjacent defects. *Int J Dermatol.* 2020;59:e58–60.
113. Jibbe A, Tolkachjov SN. An efficient single-layer suture technique for large scalp flaps. *J Am Acad Dermatol.* 2020;83:e395–6.
114. Kantor J. Dermatologists perform more reconstructive surgery in the Medicare population than any other specialist group: A cross-sectional individual-level analysis of Medicare volume and specialist type in cutaneous and reconstructive surgery. *J Am Acad Dermatol.* 2018;78:171–3.
115. Donaldson MR, Coldiron BM. Dermatologists perform the majority of cutaneous reconstructions in the Medicare pop-

- ulation: numbers and trends from 2004 to 2009. *J Am Acad Dermatol.* 2013;68:803-8.
116. Vinciullo C. Mohs micrographic surgery and multidisciplinary management. *Australas J Dermatol.* 2019;60:334-5.
117. O'Halloran L, Smith H, Vinciullo C. Periocular Mohs micrographic surgery in Western Australia 2009-2012: A single centre retrospective review and proposal for practice benchmarks. *Australas J Dermatol.* 2017;58:106-10.
118. Cohen DK, Goldberg DJ. Mohs Micrographic Surgery: Past, Present, and Future. *Dermatol Surg.* 2019;45:329-39.
119. Alawi SA, Kuck M, Wahrlich C, Batz S, Mckenzie G, Fluhr JW, et al. Optical coherence tomography for presurgical margin assessment of non-melanoma skin cancer - a practical approach. *Exp Dermatol.* 2013;22:547-51.
120. Longo C, Pampena R, Bombonato C, Gardini S, Piana S, Mirra M, et al. Diagnostic accuracy of ex vivo fluorescence confocal microscopy in Mohs surgery of basal cell carcinomas: a prospective study on 753 margins. *Br J Dermatol.* 2019;180:1473-80.